ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC) Meeting Abstract

  

Authors:	Motzer, R. J.; Lee, C. H.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U. N.; Graham, R.; Liu, S.; McCune, S.; Shaheen, M.; Parmar, H.; Shen, Y.; Whiting, S. H.; Tannir, N. M.
Abstract Title:	ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Meeting Title:	44th ESMO Congress (ESMO 2019)
Journal Title:	Annals of Oncology
Volume:	30
Issue:	Suppl. 5
Meeting Dates:	2019 Sep 27-Oct 1
Meeting Location:	Barcelona, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2019-10-01
Start Page:	mdz394.048
Language:	English
ACCESSION:	WOS:000491295500178
PROVIDER:	wos
DOI:	10.1093/annonc/mdz394.048
Notes:	Meeting Abstract: LBA54 -- Appears on pages v889-v890 of the abstract book -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/157345